Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.

In older populations with type 2 diabetes (T2D), individualised target HbA1c should be achieved with minimal hypoglycaemia, and therapies should be tested for both safety and efficacy. BRIGHT was the first head-to-head randomized trial comparing insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) in insulin-naive adults with T2D. In this sub-analysis, endpoints were studied by predefined (